Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.

[1]  J. F. Burrows,et al.  Cathepsin S from both tumor and tumor‐associated cells promote cancer growth and neovascularization , 2013, International journal of cancer.

[2]  E. Raymond,et al.  Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib , 2013, Cancer Chemotherapy and Pharmacology.

[3]  E. Ingelsson,et al.  Serum Cathepsin S Is Associated With Decreased Insulin Sensitivity and the Development of Type 2 Diabetes in a Community-Based Cohort of Elderly Men , 2012, Diabetes Care.

[4]  J. Xu,et al.  Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. , 2012, Biochemical and biophysical research communications.

[5]  K. Ng.  Potential role of odanacatib in the treatment of osteoporosis , 2012, Clinical interventions in aging.

[6]  J. Johnston,et al.  Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. , 2012, Biochimie.

[7]  J. Johnston,et al.  Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity , 2011, Molecular Cancer.

[8]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[9]  J. Johnston,et al.  The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study , 2011, British Journal of Cancer.

[10]  C. Scott,et al.  The Emerging Relevance of the Cysteine Protease Cathepsin S in Disease , 2011 .

[11]  I. Schechter,et al.  Cathepsins S, B and L with aminopeptidases display β-secretase activity associated with the pathogenesis of Alzheimer’s disease , 2011, Biological chemistry.

[12]  Alice Lee-Dutra,et al.  Cathepsin S inhibitors: 2004 – 2010 , 2011, Expert opinion on therapeutic patents.

[13]  J. Johnston,et al.  Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF , 2010, PloS one.

[14]  John J. M. Wiener,et al.  Recent advances in the design of cathepsin S inhibitors. , 2010, Current topics in medicinal chemistry.

[15]  C. Peters,et al.  Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis , 2010, Oncogene.

[16]  K. Clément,et al.  Cathepsins in Human Obesity: Changes in Energy Balance Predominantly Affect Cathepsin S in Adipose Tissue and in Circulation , 2010 .

[17]  M. Tabrizi,et al.  Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease , 2010, The AAPS Journal.

[18]  J. Johnston,et al.  Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis , 2009, Clinical Cancer Research.

[19]  J. Xu,et al.  Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. , 2009, Molecular medicine reports.

[20]  I. Bièche,et al.  Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. , 2009, Cancer research.

[21]  Yun‐Sil Lee,et al.  Radiation‐induced cathepsin S is involved in radioresistance , 2009, International journal of cancer.

[22]  B. Seliger,et al.  CIITA versus IFN-γ induced MHC class II expression in head and neck cancer cells , 2009, Archives of Dermatological Research.

[23]  A. Ray,et al.  Cysteine cathepsin S as an immunomodulatory target: present and future trends , 2008, Expert opinion on therapeutic targets.

[24]  O. De Wever,et al.  Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells , 2007, Molecular and Cellular Biology.

[25]  O. Vasiljeva,et al.  Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.

[26]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[27]  P. Hamilton,et al.  Cathepsin S expression: An independent prognostic factor in glioblastoma tumours—a pilot study , 2006, International journal of cancer.

[28]  R. Kalluri,et al.  Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.

[29]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[30]  Jean-Daniel Zucker,et al.  Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  G. Berx,et al.  The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. , 2005, Cancer research.

[32]  Bonnie F. Sloane,et al.  Cysteine cathepsins in human cancer , 2004, Biological chemistry.

[33]  P. Johnston,et al.  The clinical significance of cathepsin S expression in human astrocytomas. , 2003, The American journal of pathology.

[34]  Bonnie F. Sloane,et al.  Expression of cathepsins B and S in the progression of prostate carcinoma , 2001, International journal of cancer.

[35]  D. Brömme,et al.  Evaluation of Dipeptide α-Keto-β-aldehydes as New Inhibitors of Cathepsin S☆ , 2000 .

[36]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[37]  R. Mitchell,et al.  Cathepsin S activity regulates antigen presentation and immunity. , 1998, The Journal of clinical investigation.

[38]  S. Weiss,et al.  Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Selkoe,et al.  The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. , 1995, The American journal of pathology.

[40]  D. Rich,et al.  Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.

[41]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[42]  D. Brömme,et al.  Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S. , 2000, Biochemical and biophysical research communications.

[43]  D. Steiner,et al.  The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumors. , 1991, Biomedica biochimica acta.